Über das Unternehmen
- Firmenname (rechtlich): Shandong Longzen Pharmaceutical Co., Ltd
- Registrierungsland: China
- Adresse: China Mainland Shandong Binzhou No. 987 Yuehe 6th Road, Economic Development Zone, Gaoxin Subdistrict, Zouping City, Binzhou City, Shandong Province
- Anzahl der Mitarbeiter: 150 - 199
- Gründungsjahr: 2020
Beschreibung:
Founded in December 2020 as a venture initiated by Suzhou Medinoah (Meinuo) Pharmaceutical Technology Co., Ltd., Shandong Longzen Pharmaceutical Co., Ltd. operates a roughly 2-billion-yuan, 95,000-square-meter pharmaceutical complex in the Economic and Technological Development Zone of Zouping City, Binzhou, Shandong Province. At full capacity the site is designed to produce 572 tons of active pharmaceutical ingredients, 30 million bottles of injectables, and 2 billion oral tablets annually, combining drug research, pilot-scale, and commercial production functions aimed at cultivating new and first-generic drugs as part of a broader ambition to become a leading Chinese CXO for specialty chemical drugs. The company has built a product pipeline centered on gadobutrol, alpha-lipoic acid (including its tromethamine salt), teneligliptin hydrobromide, and melogabalin besylate: its gadobutrol API has obtained a European CEP certificate and completed Korean DMF registration, its lipoic acid API has likewise secured a CEP certificate and Korean registration, its melogabalin besylate API has been accepted for review by China's CDE, and its teneligliptin hydrobromide API is expected to complete regulatory conversion by February 2026. Backed by its parent company's R&D platform, an ICH/FDA/EMA-aligned quality system, and flexible production scaling from gram to ton quantities, the company manufactures and trades APIs, intermediates, bio products, natural extracts, finished dosage forms, excipients, dietary supplements, and food ingredients, offering CRO, CMO, CSO, and CDMO contract services. It exports to more than 30 countries (about half of total output) and serves markets across North America, Latin America, Europe, Australasia, Asia, the Middle East, and Africa.
Geschäftsaktivitäten
Pharmazeutische Wirkstoffe (API)
HerstellerVertriebspartnerDienstleisterAgentur / VertreterGroßhändlerEinzelhändlerImporteurExporteur
Fertigarzneiformen
HerstellerVertriebspartnerDienstleisterAgentur / VertreterGroßhändlerEinzelhändlerImporteurExporteur
Produktionsanlagen & Betriebstechnik
HerstellerVertriebspartnerDienstleisterAgentur / VertreterGroßhändlerEinzelhändlerImporteurExporteur
Hilfsstoffe & Zusatzstoffe
HerstellerVertriebspartnerDienstleisterAgentur / VertreterGroßhändlerEinzelhändlerImporteurExporteur
Nahrungsergänzungsmittel & Nutrazeutika
HerstellerVertriebspartnerDienstleisterAgentur / VertreterGroßhändlerEinzelhändlerImporteurExporteur
Naturextrakte & Pflanzliche Rohstoffe
HerstellerVertriebspartnerDienstleisterAgentur / VertreterGroßhändlerEinzelhändlerImporteurExporteur
Pharmazeutische Chemikalien
HerstellerVertriebspartnerDienstleisterAgentur / VertreterGroßhändlerEinzelhändlerImporteurExporteur
Biopharmazeutische Produkte
HerstellerVertriebspartnerDienstleisterAgentur / VertreterGroßhändlerEinzelhändlerImporteurExporteur
Absatzmärkte
- Western Europe: Austria, Belgium, France
- Northern America: Bermuda, Canada, Greenland, Saint Pierre and Miquelon, United States
- Central America: Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama
- South America: Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Falkland Islands, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela
Hauptprodukte/-dienstleistungen
- Pharmazeutische Wirkstoffe (API): ALPHA LIPOIC ACID, R-(+)-Lipoic Acid, Xanomeline
- Pharmazeutische Chemikalien: DOTA, Cyclen, (R)-N-Boc-3-pyrrolidineacetic acid, R-(+)-Alpha Lipoic Acid Tromethamine Salt, Mirogabalin Besylate, tert-butyl (1r,3r)-3-hydroxy-2,2,4,4-tetramethylcyclobutylcarbamate, 1-benzyl-3,3-difluoropiperidine-4,4-diol, 1,1-Dimethylethyl (αS,3R)-1-[(1,1-dimethylethoxy)carbonyl]-α-[(3-hydroxyphenyl)methyl]-3-pyrrolidineacetate, 1,4-Dioxa-8-azaspiro[4.5]decane hydrochloride, 1,4-Oxazepan-5-one, 3-(1-oxo-5-(piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione hydrochloride, 3-ethylbicyclo[3.2.0]hept-3-en-6-one, 3-Fluorophenethylamine, 3-Hydroxy-2, 2,4,4-(tetramethoxy) cyclobutylcarbamate tert-butyl trans-tert-Butyl, 3-hydroxy-2,2,4,4-(tetraMethyl)cyclobutylcarbaMatetrans-tert-Butyl 3-hydroxy-2,2,4,4-(tetraMethyl)cyclobutylcarbaMate, 3-Pyrrolidineacetic acid, α-[[3-(2-aminoethoxy)phenyl]methyl]-1-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester, (αS,3R)-, 4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-2-fluoro-3-methylaniline, 4-Chloro-6-hydroxyquinazoline, 6-fluoro-3,4-dihydroisoquinolin-1(2H)-one, 7-bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one, 7-Bromo-6-chloro-1,3-dihydroisobenzofuran-5-amine, 7-Chloro-[1,2,4]triazolo[1,5-a]pyridine, Calcobutrol, Carbamic acid, N-[3-cyano-7-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thien-2-yl]-, 1,1-dimethylethyl ester, Ethyl 6,8-dichloroctanoate, Ethyl 6,8-dichlorooctanoateEthyl 6,8-dichlorooctanoate, Ethyl 6,8-dichlorooctanoate, Gadolinium, [10-[2-(hydroxy-kO)-3-hydroxy-1-(hydroxymethyl)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-kN1,kN4,kN7,kN10,kO1,kO4,kO7]-,monohydrate,[SA-8-1425362'5'-(R*,S*)]- (9CI), Gadoterate Meglumine, Gadoteric acid, (R)-2-(2,5-difluorophenyl)pyrrolidine (R)-2-hydroxysuccinate, Teneligliptin Hydrobromide, tert-butyl 4-(6-aminopyridin-3-yl)piperidine-1-carboxylate, tert-butyl N-(4-bromo-3-cyano-7-fluoro-benzothiophen-2-yl)carbamate, tert-Butyl (S)-3-(2-hydroxyethyl)piperazine-1-carboxylate, (S)-tert-Butyl3-(2-hydroxyethyl)piperazine-1-carboxylate(S)-tert-Butyl3-(2-hydroxyethyl)piperazine-1-carboxylate
- ATC-Klassifikation (Anatomisch-Therapeutisch-Chemisch): Ticagliptin hydrobromide, Teneligliptin HydrobromideTeneligliptin Hydrobromide
Unsere Produkte & Dienstleistungen
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
![1,4-Dioxa-8-azaspiro[4.5]decane hydrochloride](/_next/image?url=https%3A%2F%2Fapi.pharmacountry.com%2Fuploads%2Fitems%2F14-dioxa-8-azaspiro45decane-hydrochlorid-376311.jpg&w=640&q=75)
Sell · Pharma Chemicals
Shandong Longzen Pharmaceutical Co., Ltd
China3-Hydroxy-2, 2,4,4-(tetramethoxy) cyclobutylcarbamate tert-butyl trans-tert-Butyl, 3-hydroxy-2,2,4,4-(tetraMethyl)cyclobutylcarbaMatetrans-tert-Butyl 3-hydroxy-2,2,4,4-(tetraMethyl)cyclobutylcarbaMate
Manufacturer: Shandong Longzen Pharmaceutical Co., Ltd, China
![3-Pyrrolidineacetic acid, α-[[3-(2-aminoethoxy)phenyl]methyl]-1-[(1,1-dimethylethoxy)carbonyl]-, 1,1-dimethylethyl ester, (αS,3R)-](/_next/image?url=https%3A%2F%2Fapi.pharmacountry.com%2Fuploads%2Fitems%2F3-pyrrolidineacetic-acid--3-2-aminoethox-376317.jpg&w=640&q=75)
Sell · Pharma Chemicals
![Carbamic acid, N-[3-cyano-7-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thien-2-yl]-, 1,1-dimethylethyl ester](/_next/image?url=https%3A%2F%2Fapi.pharmacountry.com%2Fuploads%2Fitems%2Fcarbamic-acid-n-3-cyano-7-fluoro-4-4455--376319.jpg&w=640&q=75)
Sell · Pharma Chemicals
Shandong Longzen Pharmaceutical Co., Ltd
ChinaGadolinium, [10-[2-(hydroxy-kO)-3-hydroxy-1-(hydroxymethyl)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-kN1,kN4,kN7,kN10,kO1,kO4,kO7]-,monohydrate,[SA-8-1425362'5'-(R*,S*)]- (9CI)
Manufacturer: Shandong Longzen Pharmaceutical Co., Ltd, China
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Pharma Chemicals
Sell · Pharma Chemicals
Sell · ATC (Anatomical Therapeutic Chemical) Classification
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Pharma Chemicals
Certifications
CEP certificate
Bewertungen
(0)
(0)
(0)
(0)
(0)
Kommentare
Filter:
Sortieren nach:
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen